National Taiwan University NAC Noise-Induced Hearing Loss Study

Academic randomized crossover Phase 2 study evaluating oral N-acetylcysteine 1200 mg/day as antioxidant prophylaxis for temporary threshold shift in noise-exposed workers. Glucose was the placebo comparator, not a separate hearing-loss pipeline program.

Promoted from needs-review after confirming ClinicalTrials.gov, registry mirror, and publication-backed context. This remains an institution-led generic-repurposing study-level record, not an active commercial NAC product program. Glucose is the placebo comparator and should not appear as a standalone HearScape therapeutic program.